Clinical Trial Update: Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating Imdusiran (AB-729) for chronic hepatitis B is recruiting, with assessments of intrahepatic and peripheral responses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Imdusiran (AB-729) (Imdusiran)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Chronic Hepatitis B | Phase 2 | Status: RECRUITING